Anxo Pharmaceutical Co (ROCO:6677) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6677 Anxo Pharmaceutical Co Ltd ROCO:6677
69 GF Score
Price NT$20.50
GF Value NT$24.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anxo Pharmaceutical Co  (ROCO:6677) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.24 0.96

Anxo Pharmaceutical Co Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.24 0.87 0.96 0.82

ROCO:6677 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


ROCO:6677
69GF Score
Anxo Pharmaceutical Co Ltd ROCO:6677
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anxo Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Anxo Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Anxo Pharmaceutical Co's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=15.089/324.0540*324.0540
=15.089

Current CPI (Dec25) = 324.0540.

Anxo Pharmaceutical Co Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 13.766 241.432 18.477
201712 15.122 246.524 19.878
201812 18.233 251.233 23.518
201912 18.861 256.974 23.784
202012 17.382 260.474 21.625
202112 16.394 278.802 19.055
202212 17.347 296.797 18.940
202312 18.219 306.746 19.247
202412 16.068 315.605 16.498
202512 15.089 324.054 15.089

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?

Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$20.50 is trading 15.1% below its estimated GF Value™ of NT$24.15. GuruFocus considers Anxo Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for ROCO:6677:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$24.15 vs. price of NT$20.50 (15.1% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anxo Pharmaceutical Co Business Description

Address 8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
69GF Score

Get the complete analysis for ROCO:6677

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.50
Price
NT$24.15
GF Value